Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Incontinence is big business—Boston Scientific valued (PDF) the prosthetic urology and pelvic floor markets at a combined $1.1 billion last year—but could be bigger if more men were aware of ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed. Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported ...